The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays.
about
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population.The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study.HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological dataValidation of human papillomavirus genotyping by signature DNA sequence analysis.Impact of improved classification on the association of human papillomavirus with cervical precancer.Update on prevention and screening of cervical cancer.Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancerClinical application of DNA ploidy to cervical cancer screening: A review.From Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice.Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis.Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories.The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage studyInvited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath™ liquid-based pap specimensHuman papillomavirus genotype specificity of hybrid capture 2Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia.Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort.The evolving definition of carcinogenic human papillomavirus.Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV typesEvaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping.Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.Special commentary: patient safety and the next generation of HPV DNA tests.Commercially available assays for multiplex detection of alpha human papillomaviruses.Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.Understanding HPV tests and their appropriate applications.Nucleic acid-based assays for the detection of high-risk human papillomavirus: a technical review.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.Improving Laboratory Efficiency by Automation of Preanalytic Processing of ThinPrep Specimens for Real-Time PCR High-Risk HPV Testing.Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.Clinical validation of a novel real-time human papillomavirus assay for simultaneous detection of 14 high-risk HPV type and genotyping HPV type 16 and 18 in China.
P2860
Q24607403-ADD3304F-EAEA-4BF2-BBF7-6CF683387DEDQ26828840-2603D184-FB7D-43F3-A0F6-6A39455A11D3Q30301116-CCA27E29-7647-43A6-86CF-85FABF824746Q30454956-5D9551EC-D12D-4479-BB80-747CEA1E0F09Q31121182-1F563DA0-537E-4FA5-92B9-BCEF9845B613Q33450984-7165CB25-284C-4D4C-827D-F2D94BA85B54Q33883581-E7B22EE3-E68D-43EC-A392-60EA78BD9628Q34031269-9AC9029D-739B-4D14-9469-ECEE9592758EQ34046296-6E89FC86-0197-4EC7-AC7C-27979E239E01Q34596772-2EA5A275-7010-4448-AECA-EBAFD29AA265Q34657755-848FA505-D1F0-40C2-B5AD-CFF699AD37A0Q34774870-A6BA08D2-0DA2-41DA-8E99-902FF7F6BAC0Q34913072-5919E624-0571-45DA-AB28-68FFAACE927BQ35066533-AE4E4703-A374-45B2-8569-FDE1D3F09003Q35139772-32761C53-D8EA-4B93-9C41-9C84ACFFDB8DQ35356381-1B52E088-EBE0-4707-8362-FC2BA6EAB287Q35757654-8B883D95-C3F3-455C-9F3D-43CD68F34BC4Q35847330-72B4A210-056B-4CCC-9883-751FDB8097A4Q36029632-A1A7C815-E42C-4458-AB1A-86EEE6119438Q36395656-BD15168F-A7E5-4669-B96E-03EF6786DE99Q36423668-81791B00-181F-4699-8353-531F40AFC5ACQ36743797-43C659A2-D354-48A2-BFFA-5F5C957E3DBFQ36753225-893F3DAD-6C4B-4741-BF28-08DFE358D6C4Q36845399-0C3B9C9B-4631-4BE1-83D3-09C5532E854CQ36933532-DB1411F3-6FA5-42EE-8CF1-22A74C0E35B3Q37091121-879E1744-2164-464A-A545-75EF21CC452FQ37195383-602C4A01-1131-45AB-9F6C-A40C94A7B850Q37202940-550A962B-F3A9-4C04-8393-4B1006D85B82Q37295681-7963712D-AF54-4C36-977C-F4B570D27E20Q37374869-AB012171-CAB9-4952-924C-4952E5F68FABQ37461977-F6405E58-EF21-47D2-B50C-DF610AA5B9C1Q37775801-F350CE2C-7C70-4794-A21C-C3322DEB3D05Q37800921-B1A3A2AE-00C1-43F5-904A-B3EC60BA4B7EQ37896031-961DACE3-30C2-4168-B728-E03448AAD84CQ38133612-CCF35302-C836-4AFC-941B-36AE99C0D55FQ38221059-062066D9-B2A5-45B0-ADA9-367943E4B1ABQ38258014-EC9214A1-DD85-44B3-BBEB-FABEB045E74AQ38387930-4E0B30FF-5C90-4B69-B28C-28DAC0C84F5EQ40861259-065A16D7-EAD3-46C0-9B80-7BEBD28EF3ADQ40906283-F629FA54-E1DB-479D-B8A9-C6127B7D90DF
P2860
The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The expanded use of HPV testin ...... use of well-validated assays.
@ast
The expanded use of HPV testin ...... use of well-validated assays.
@en
type
label
The expanded use of HPV testin ...... use of well-validated assays.
@ast
The expanded use of HPV testin ...... use of well-validated assays.
@en
prefLabel
The expanded use of HPV testin ...... use of well-validated assays.
@ast
The expanded use of HPV testin ...... use of well-validated assays.
@en
P2093
P356
P1476
The expanded use of HPV testin ...... use of well-validated assays.
@en
P2093
American Society for Colposcopy and Cervical Pathology
Diane Solomon
Mark H Stoler
Philip E Castle
P304
P356
10.1309/RNF3C01JKADQCLKP
P407
P577
2007-03-01T00:00:00Z